|
|
|
| Analysis on the Effects and Safety of Huangqi Capsule Assisted with Cefoperazone-sulbactam and Tigecycline in the treatment of MDRAB Pneumonia |
| YANG Shuai, ZHANG Mingyue, KANG Mengjie, et al |
| Beijing Shijitan Hospital Affiliated to Capital Medical University, Beijing 10003, China |
|
|
|
|
Abstract Objective: To explore the effects and safety of Huangqi capsule combined with cefoperazone-sulbactam and tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii (MDRAB) pneumonia. Methods: The clinical data of 52 cases of MDRAB pneumonia treated with cefoperazone sulbactam + tegacyclin (control group) and Huangqin capsule + cefoperazone sulbactam + tegacyclin (observation group) were analyzed retrospectively. The bacterial clearance, state of recovery (time of normal temperature recovery, Rale disappearance, lung shadow disappearance) and adverse reactions were recorded, and the infection status (PCT, MMP-9), TCM syndrome (tcmsss), lung injury (lung injury) were compared before and after treatment for 2 weeks Score (LIS)] difference. Results: The bacterial clearance in observation group was significantly better than that in control group (P<0.05), and the normal recovery time of body temperature, disappearance time of rales, disappearance time of lung shadow and total incidence rate of adverse reactions during treatment were significantly lower than those in control group (P<0.05). After 2周 of treatment, the scores of infection status (serum PCT, MMP-9), TCM syndrome (TCMSSS score) and lung injury (LIS score) were lower than those before treatment (P<0.05), and the scores in observation group were lower than those in control group (P<0.05). Conclusion: Huangqi capsule assisted with cefoperazone-sulbactam and tigecycline has significant effects in the treatment of MDRAB pneumonia, and it can also reduce the risk of adverse reactions and has high clinical application value.
|
|
|
|
|
|
[1] 徐娟,殷勇,赵丽霞,等.社区获得性肺炎患儿感染多重耐药菌的危险因素评估模型[J].医学综述,2018,24(4):804~811.
[2] 黄金文,刘厚明.急性脑卒中患者医院感染鲍氏不动杆菌耐药性探讨[J].中国实验诊断学,2017,21(3):429~431.
[3] 马文杰,陈勇,吴镝,等.多药耐药鲍氏不动杆菌相关肺部感染的抗菌药物使用分析[J].中华医院感染学杂志,2018,28(5):675~678.
[4] 陈佰义,何礼贤,胡必杰,等.中国鲍曼不动杆菌感染诊治与防控专家共识[J].中华医学杂志,2012,92(2):76~85.
[5] 郑筱萸.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002.179~181.
[6] 崔英海,姚明,李丁蕾,等.清金化痰汤对重症肺炎(痰热壅肺证)患者中医证候评分量表评分及炎性反应递质的影响[J].世界中医药,2018,13(11):161~164.
[7] 王琦.支气管肺泡灌洗地塞米松联合痰热清注射液治疗急性肺损伤疗效及对血浆和肺泡灌洗液炎性因子的影响[J].现代中西医结合杂志,2017,26(19):2093~2096.
[8] 李双,张广庆,刘玉才,等.替加环素不同治疗方案对ICU泛耐药鲍曼不动杆菌肺部感染的临床效果对比观察[J].中国抗生素杂志,2018,43(2):139~145.
[9] 李儒,王旭明,郭红荔,等.替加环素联合头孢哌酮舒巴坦对多重耐药鲍曼不动杆菌肺部感染患者的临床疗效及机制探讨[J].中国医院药学杂志,2017,37(5):450~453.
[10] 刘彦晶,张雅洁,纪雪,等.中药黄芩对NDM-1乙酸钙不动杆菌的抑菌及质粒消除的研究[J].中国药学杂志,2017,52(12):1018~1022.
[11] 庄雅娟,李云超,贯丽娟,等.替加环素联合小青龙汤雾化吸入治疗耐药鲍曼不动杆菌致呼吸机相关性肺炎疗效及对血清炎性因子的影响[J].现代中西医结合杂志,2018,27(5):492~494,570. |
|
|
|
2020, Vol. 26 
